Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Recruiting 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2Sarcoma 1NET 1Gynecologic 1Genitourinary 1Endocrine 1Breast 1

Conditions

Bile Duct Neoplasms 2Vulvar Neoplasms 1Sarcoma 1Prostatic Neoplasms 1Ovarian Neoplasms 1Neuroendocrine Tumors 1Hereditary Sensory and Autonomic Neuropathies 1Gastrointestinal Neoplasms 1Gallbladder Neoplasms 1Disease 1Colorectal Neoplasms 1Cholangiocarcinoma 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Neuroendocrine 1Carcinoma, Hepatocellular 1Breast Neoplasms 1Advanced Adult Hepatocellular Carcinoma 1

Interventions

Gemcitabine 3Capecitabine 3tivozanib 2pembrolizumab 2Oxaliplatin 2Cisplatin 2trametinib 1tislelizumab 1spartalizumab 1silmitasertib 1pertuzumab 1olutasidenib 1devimistat 1atezolizumab 1Sorafenib 1Ritonavir 1Pemetrexed 1Nivolumab 1Itraconazole 1Ipilimumab 1Epirubicin 1Carboplatin 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Bile Duct Neoplasms × tivozanib × Clear all
NCT04645160 2026-06-05

Evaluating Efficacy of Tivozanib (AV-951) in Biliary Tract Cancers

National Institutes of Health Clinical Center (CC)

Phase 1/2 Recruiting
31 enrolled
Gastrointestinal

Bile Duct Neoplasms, Hereditary Sensory and Autonomic Neuropathies, Cholangiocarcinoma

NCT05000294 2026-06-05

Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types

University of Florida

Phase 1/2 Recruiting
29 enrolled
BreastEndocrineGastrointestinalGenitourinaryGynecologicNETSarcoma

Bile Duct Neoplasms, Breast Neoplasms, Gallbladder Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Sarcoma, Vulvar Neoplasms, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡